PPADS (tetrasodium)

PPADS tetrasodiuma is a non-selective P2X receptor antagonist. PPADS tetrasodiuma blocks recombinant P2X1, -2, -3, -5 with IC50s ranging from 1 to 2.6 μM. PPADS tetrasodiuma blocks native P2Y2-like (IC50~0.9 mM) and recombinant P2Y4 (IC50~15 mM) receptors. PPADS tetrasodiuma is an inhibitor of the reverse mode of the Na/Ca2+ exchanger in guinea pig airway smooth muscle[1][2].

Product Specifications

CAS Number

[192575-19-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Na+/Ca2+ Exchanger; P2X Receptor

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Purity

99.9

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(/N=N/C2=NC(C)=C(O)C(C=O)=C2COP(O[Na])(O[Na])=O)C(S(=O)(O[Na])=O)=C1)(O[Na])=O

Molecular Formula

C14H10N3Na4O12PS2

Molecular Weight

599.30

Precautions

H315, H319, H335

References & Citations

[1]Flores-Soto E, et al. PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. Eur J Pharmacol. 2012 Jan 15;674 (2-3) :439-44.|[2]Huo H, et al. Mapping the binding site of the P2X receptor antagonist PPADS reveals the importance of orthosteric site charge and the cysteine-rich head region. J Biol Chem. 2018 Aug 17;293 (33) :12820-12831.|[3]Einfluss von ATP und seinen Derivaten auf die Aktivierung von Monozyten.|[4]Rost S, et al. P2 receptor antagonist PPADS inhibits mesangial cell proliferation in experimental mesangialproliferative glomerulonephritis. Kidney Int. 2002 Nov;62 (5) :1659-71.